{"id":690848,"date":"2022-09-30T16:15:31","date_gmt":"2022-09-30T20:15:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/"},"modified":"2022-09-30T16:15:31","modified_gmt":"2022-09-30T20:15:31","slug":"clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/","title":{"rendered":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3"},"content":{"rendered":"<h2>\nConference Call and Webcast Set for 8:30 a.m. EDT<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SALT LAKE CITY, Sept.  30, 2022  (GLOBE NEWSWIRE) &#8212; Clene Inc.\u00a0(NASDAQ: CLNN) along with its subsidiaries \u201cClene\u201d and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8\u00ae regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene\u2019s management team will host a conference call and webcast to discuss the results.<\/p>\n<p>\n        <strong>Conference Call and Webcast Details<\/strong><br \/>\n        <br \/>Time and Date: 8:30 a.m. EDT on Oct. 3, 2022<br \/>Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)<br \/>Conference ID: 5318408<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AE5VsOj0ed-GUwjmcRAYSmEWziw6iZvVaSRi1DFuPuTyPhlaVpGG8EeCquzSNnT_SmvjwkmqJgI9HIgpiAdY6GbmCjNkX-v8UD_xBfPgFHq7b82IKaOiUXeZykdQxV8uTSbwZ5yDEAvZZB-2xuEaJTQrulNTSbjwfOZ6ZC0cIwacuZcfQVM2-d3bH0yT_Ugc4QfhYj476BF6kQIYTzgMIGEcBTtyItvGp4Mhg-YQEvDC6yvuSJAkjOARVBaqsBNuVSmaODInL3zXAAu-K6jNXQ==\" rel=\"nofollow noopener\" target=\"_blank\">Webcast Link<\/a><\/p>\n<p>A live audio webcast can be accessed by visiting the Investors section of the Company\u2019s website on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qxQvicfSNWYYeqlAE8PxZJBeaHVz3rMpskpnORQ8uQx9mAiym38wbM6OyPI5VJDmDqRV24_fjsKUGhT0HiE8xKgs1QTxlLaVoxrWe08DWXHXXfo0Bgi-2VDmFaThO6pWAaZ6g3ciAdjyjYDFIuLDmxTsq0iJjflH_SWROKIOYIE=\" rel=\"nofollow noopener\" target=\"_blank\">Events page<\/a>. An archived webcast will be available on the website approximately two hours after the event.<\/p>\n<p>\n        <strong>About CNM-Au8\u00ae<\/strong><br \/>\n        <br \/>CNM-Au8 is Clene\u2019s lead asset in mid- and late-stage clinical development for the treatment of multiple sclerosis and amyotrophic lateral sclerosis. An oral suspension of gold nanocrystals, CNM-Au8 was developed to protect neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8\u00ae is a federally registered trademark of Clene Nanomedicine, Inc.<\/p>\n<p>\n        <strong>About Clene<\/strong><br \/>\n        <br \/>Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&amp;D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_iHzXC6_LthLzNdU9iOIKE5UWCRAl8Q0iRD53w3yZdtYFARVYsRCQBUDQoA07kkrITJFI9Fz5VG6SCfKhUHeyA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jfrXh-B8tWBptCwMQOAnqITMLHSaxK6lOhXiRmmsT5PXTaMIJAmytO8z1h9TkC_6vyql7wiVynI1ISpjdT9V69PnBe8W7fv6S7CChQMHIHJu_iZy6drQk--NvmfCnUCV\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GkbtHPDoGHjm76EE2dK8ZOPFJLHLXgKAaMailPiPUqHs7dtrcvs3UjYyhBcWcsPIGcXu3mtmapORuEcCL9GvU09ZlU-7sczZLE_6va9mtJI=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook.<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<br \/><\/strong>This press release contains \u201cforward-looking statements\u201d within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the \u201csafe harbor\u201d provisions created by those laws. Clene\u2019s forward-looking statements include, but are not limited to, statements regarding our or our management team\u2019s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in \u201cRisk Factors\u201d in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that \u201cwe believe\u201d and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <u>Media Contact<\/u><br \/>\n            <\/strong><br \/>\n            <br \/>Ignacio Guerrero-Ros, Ph.D., or David Schull<br \/>Russo Partners, LLC<br \/><a href=\"mailto:Ignacio.guerrero-ros@russopartnersllc.com\" rel=\"nofollow noopener\" target=\"_blank\">Ignacio.guerrero-ros@russopartnersllc.com<\/a><br \/><a href=\"mailto:David.schull@russopartnersllc.com\" rel=\"nofollow noopener\" target=\"_blank\">David.schull@russopartnersllc.com<\/a><br \/>(858) 717-2310<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <u>Investor Contact<\/u><br \/>\n            <\/strong><br \/>\n            <br \/>Kevin Gardner<br \/>LifeSci Advisors<br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><br \/>617-283-2856<\/td>\n<\/tr>\n<\/table>\n<p>Source: Clene Inc.<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzA0N2FlNWYtZWNiYS00NTYzLTk4MzYtNjk4NDFlMjZhNDMwLTEyNTc5OTk=\/tiny\/Clene-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast Set for 8:30 a.m. EDT SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) &#8212; Clene Inc.\u00a0(NASDAQ: CLNN) along with its subsidiaries \u201cClene\u201d and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8\u00ae regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene\u2019s management team will host a conference call and webcast to discuss the results. Conference Call and Webcast Details Time and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio webcast can be accessed by visiting the Investors &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690848","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Set for 8:30 a.m. EDT SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) &#8212; Clene Inc.\u00a0(NASDAQ: CLNN) along with its subsidiaries \u201cClene\u201d and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8\u00ae regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene\u2019s management team will host a conference call and webcast to discuss the results. Conference Call and Webcast Details Time and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio webcast can be accessed by visiting the Investors &hellip; Continue reading &quot;Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T20:15:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3\",\"datePublished\":\"2022-09-30T20:15:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/\"},\"wordCount\":845,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/\",\"name\":\"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\",\"datePublished\":\"2022-09-30T20:15:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/","og_locale":"en_US","og_type":"article","og_title":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk","og_description":"Conference Call and Webcast Set for 8:30 a.m. EDT SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) &#8212; Clene Inc.\u00a0(NASDAQ: CLNN) along with its subsidiaries \u201cClene\u201d and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8\u00ae regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene\u2019s management team will host a conference call and webcast to discuss the results. Conference Call and Webcast Details Time and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio webcast can be accessed by visiting the Investors &hellip; Continue reading \"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-30T20:15:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3","datePublished":"2022-09-30T20:15:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/"},"wordCount":845,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/","name":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=","datePublished":"2022-09-30T20:15:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1Njg3NCM1MTgxNjk5IzIyNDY0NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690848"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690848\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}